Immediate Impact
1 standout
Citing Papers
Neoantigens: promising targets for cancer therapy
2023 Standout
Works of Peter Wells-Jordan being referenced
A phase II trial of abemaciclib in patients with p16ink4a negative, relapsed mesothelioma.
2021
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Peter Wells-Jordan | 6 | 5 | 17 | 7 | 20 | |
| Amy Branson | 3 | 5 | 16 | 5 | 17 | |
| Cindy Liu | 5 | 2 | 10 | 7 | 27 | |
| Junichi Ochi | 6 | 19 | 7 | 23 | ||
| Timothy Langford | 6 | 2 | 8 | 7 | 19 | |
| Rachel Lloyd | 8 | 12 | 7 | 15 | ||
| Rawan Al-Lozi | 3 | 15 | 7 | 19 | ||
| Marie Kassapian | 16 | 13 | 6 | 20 | ||
| C. Anger | 11 | 8 | 9 | 18 | ||
| Omar Ragy | 2 | 15 | 9 | 25 | ||
| Gerd Nettekoven | 6 | 7 | 7 | 16 |
All Works
Loading papers...